文献速递眼底病与葡萄膜炎眼整形与眼眶

玻璃体腔注射抗血管内皮生长因子后上睑下垂的发生率

Incidence of Blepharoptosis Following Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
PubMed 文献 · Am J Ophthalmol · 2024-03-08

回顾性队列研究纳入1100例接受至少1次玻璃体腔抗血管内皮生长因子(anti-VEGF)注射的渗出型年龄相关性黄斑变性(AMD)患者和2258例未注射的非渗出型AMD患者,比较上睑下垂发生率;注射组18/1100(1.6%)vs 非注射组52/2258(2.3%)(P = .25);注射组内使用开睑器者8/444(1.8%)vs 未使用开睑器者11/537(2.0%)(P = .82),均无统计学显著差异。

要点

  • 注射组上睑下垂18/1100(1.6%)vs 非注射组52/2258(2.3%),P = .25,无统计学显著差异。
  • 注射组内未使用开睑器者11/537(2.0%)vs 使用开睑器者8/444(1.8%),P = .82,无统计学显著差异。
  • 注射组上睑下垂多为双侧,平均于首次注射后22.4个月、且超过1年无注射期后诊断。

核心结论

  • 上睑下垂发生率无统计学显著差异,本分析中玻璃体腔anti-VEGF注射或注射时使用开睑器似乎均不增加上睑下垂风险。

研究设计与样本

  • 回顾性队列研究,使用ICD-10编码识别渗出型AMD接受至少1次玻璃体腔anti-VEGF注射的患者1100例,以及未接受注射的非渗出型AMD患者2258例作为对照。

主要发现

  • 注射组18/1100(1.6%)发生上睑下垂,非注射组52/2258(2.3%)发生上睑下垂(P = .25)。
  • 注射组内未使用开睑器者11/537(2.0%)发生上睑下垂,使用开睑器者8/444(1.8%)发生上睑下垂(P = .82)。
  • 注射组上睑下垂多为双侧,平均于首次注射后22.4个月诊断,且诊断前有超过1年无注射期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the incidence of blepharoptosis after intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections and compare the rates of blepharoptosis between patients injected with an eyelid speculum and those injected without a speculum. DESIGN: Retrospective cohort study. METHODS: International Classification of Diseases, Tenth Revision (ICD-10), codes were used to identify patients with exudative age-related macular degeneration (AMD) and those who developed ptosis after intravitreal injections. Patients with nonexudative AMD who did not receive intravitreal injections served as controls. The outcomes were the incidence of ptosis in the injection group compared to the noninjection group and incidence of ptosis in patients whose injections were performed with an eyelid speculum as compared to those whose injections were performed without a speculum. RESULTS: We recruited 1100 exudative AMD patients who received at least 1 intravitreal anti-VEGF injection and 2258 nonexudative AMD patients who had not received an injection. In the injection group, 18 of 1100 patients (1.6%) developed ptosis, compared with 52 of 2258 patients (2.3%) in the noninjection group (P = .25). Within the injection group, ptosis was mostly bilateral, diagnosed on average 22.4 months after the initial injection, and after more than a 1-year injection-free period. Eleven of 537 patients (2.0%) injected without a speculum developed ptosis, compared with 8 of 444 patients (1.8%) injected with a speculum (P = .82). CONCLUSIONS: No statistically significant differences in incidence rates of ptosis were observed. In this analysis, neither intravitreal anti-VEGF injections nor speculum use during injections appears to increase the risk of ptosis.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Lee AY, Kovacs K, Orlin A, et al. Incidence of Blepharoptosis Following Intravitreal Anti-Vascular Endothelial Growth Factor Injections. Am J Ophthalmol. 2024. PMID: 38461944. doi:10.1016/j.ajo.2024.02.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。